Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...